This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sosman, J. A. Articles by Sondak, V. K. Search for Related Content PubMed PubMed Citation Articles by Sosman, J. A. Articles by Sondak, V. K. Social Bookmarking                            What's this?

Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Impact of HLA Class I Antigen Expression on Outcome

From the Vanderbilt University, Nashville, TN; Southwest Oncology Group Statistical Center and University of Washington, Seattle, WA; Karmanos Cancer Institute, Wayne State University, Detroit, and University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; and University of Southern California and University of California Los Angeles Immunogenetics Center, Los Angeles, CA.

Address reprint requests to Publications Specialist, Southwest Oncology Group (SWOG-9035), 14980 Omicron Dr, San Antonio, TX 78245-3217.

PURPOSE: An association between expression of two of five HLA class I antigens (HLA-A2, HLA-A28, HLA-B44, HLA-B45, and HLA-C3; collectively called M5) and response to an allogeneic melanoma vaccine (Melacine; Corixa Corporation, Seattle, WA) has been described in stage IV melanoma. This study investigated whether class I antigen expression impacted relapse-free survival (RFS) after adjuvant therapy with this vaccine.

PATIENTS AND METHODS: We performed class I (HLA-A, HLA-B, and HLA-C) serotyping on patients enrolled onto Southwest Oncology Group Trial 9035, a randomized, observation-controlled, phase III trial of adjuvant Melacine. All patients had clinically node-negative cutaneous melanoma (1.5 to 4.0 mm). Interactions between treatment and class I antigen expression were tested. Analyses involved all serotyped patients and were adjusted for tumor thickness, method of nodal staging, sex, ulceration, and primary tumor site.

RESULTS: HLA typing was performed on 553 (80%) of the 689 enrolled patients (294 vaccinated and 259 observed). Expression of two M5 antigens was associated with a superior vaccine treatment effect. Among patients who matched two of the M5, the 97 vaccine-treated patients had improved RFS compared with the 78 observation patients (5-year relapse-free survival, 83% v 59%; P = .0002). The major components of this effect were contributed by HLA-A2 and HLA-C3. Among those who were HLA-A2–positive and/or HLA-C3–positive, the 5-year RFS for vaccinated patients was 77%, compared with 64% for observation (P = .004). There was no impact of HLA-A2 and/or HLA-C3 expression among observation patients.

CONCLUSION: This prospective analysis indicates a highly significant benefit of adjuvant therapy with Melacine among patients expressing two of the M5 class I antigens, validating a prior observation in stage IV disease. HLA-A2 and HLA-C3 contributed most to this effect. Processed melanoma peptides found in Melacine may be presented by HLA-A2 and HLA-C3 and play a role in preventing relapse in vaccinated patients.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. A. Sosman In Reply: J. Clin. Oncol., December 20, 2008; 26(36): 6010 - 6011. [Full Text] [PDF]

				M. S. Mitchell In Reply J. Clin. Oncol., October 10, 2007; 25(29): 4693 - 4695. [Full Text] [PDF]

				K. Y. Tsai Systemic Adjuvant Therapy for Patients With High-Risk Melanoma Arch Dermatol, June 1, 2007; 143(6): 779 - 782. [Full Text] [PDF]

				M. S. Mitchell, J. Abrams, J. A. Thompson, M. Kashani-Sabet, R. C. DeConti, W.-J. Hwu, M. B. Atkins, E. Whitman, M. S. Ernstoff, F. G. Haluska, et al. Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma J. Clin. Oncol., May 20, 2007; 25(15): 2078 - 2085. [Abstract] [Full Text] [PDF]

				D. Schadendorf, S. Ugurel, B. Schuler-Thurner, F. O. Nestle, A. Enk, E.-B. Brocker, S. Grabbe, W. Rittgen, L. Edler, A. Sucker, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG Ann. Onc., April 1, 2006; 17(4): 563 - 570. [Abstract] [Full Text] [PDF]

				V. K. Sondak, M. S. Sabel, and J. J. Mule Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin. Cancer Res., April 1, 2006; 12(7 Pt 2): 2337s - 2341s. [Abstract] [Full Text] [PDF]

				M. L. Disis and H. K. Lyerly Global Role of the Immune System in Identifying Cancer Initiation and Limiting Disease Progression J. Clin. Oncol., December 10, 2005; 23(35): 8923 - 8925. [Full Text] [PDF]

				H. Tsao, M. B. Atkins, and A. J. Sober Management of Cutaneous Melanoma N. Engl. J. Med., September 2, 2004; 351(10): 998 - 1012. [Full Text] [PDF]

				J. A. Sosman, A. T. Weeraratna, and V. K. Sondak When Will Melanoma Vaccines Be Proven Effective? J. Clin. Oncol., February 1, 2004; 22(3): 387 - 389. [Full Text] [PDF]

				M. S. Mitchell, J. Kan-Mitchell, P. R. Morrow, D. Darrah, V. E. Jones, and M. F. Mescher Phase I Trial of Large Multivalent Immunogen Derived from Melanoma Lysates in Patients with Disseminated Melanoma Clin. Cancer Res., January 1, 2004; 10(1): 76 - 83. [Abstract] [Full Text] [PDF]

				S. M. Santini and F. Belardelli Advances in the Use of Dendritic Cells and New Adjuvants for the Development of Therapeutic Vaccines Stem Cells, July 1, 2003; 21(4): 495 - 505. [Abstract] [Full Text] [PDF]

				G. Parmiani, L. Pilla, C. Castelli, and L. Rivoltini Vaccination of patients with solid tumours Ann. Onc., June 1, 2003; 14(6): 817 - 824. [Abstract] [Full Text] [PDF]

				J. W. Smith II, E. B. Walker, B. A. Fox, D. Haley, K. P. Wisner, T. Doran, B. Fisher, L. Justice, W. Wood, J. Vetto, et al. Adjuvant Immunization of HLA-A2-Positive Melanoma Patients With a Modified gp100 Peptide Induces Peptide-Specific CD8+ T-Cell Responses J. Clin. Oncol., April 15, 2003; 21(8): 1562 - 1573. [Abstract] [Full Text] [PDF]

				U. Vaishampayan, J. Abrams, D. Darrah, V. Jones, and M. S. Mitchell Active Immunotherapy of Metastatic Melanoma with Allogeneic Melanoma Lysates and Interferon {alpha} Clin. Cancer Res., December 1, 2002; 8(12): 3696 - 3701. [Abstract] [Full Text] [PDF]

				P. Hersey, A. S. Coates, W. H. McCarthy, J. F. Thompson, R. W. Sillar, R. McLeod, P. G. Gill, B. J. Coventry, A. McMullen, H. Dillon, et al. Adjuvant Immunotherapy of Patients With High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial J. Clin. Oncol., October 15, 2002; 20(20): 4181 - 4190. [Abstract] [Full Text] [PDF]

				V. K. Sondak and A. E. Chang Melanoma and Human Leukocyte Antigen Status: The Missing Link? Ann. Surg. Oncol., October 1, 2002; 9(8): 723 - 724. [Full Text] [PDF]

				V. K. Sondak, P.-Y. Liu, R. J. Tuthill, R. A. Kempf, J. M. Unger, J. A. Sosman, J. A. Thompson, G. R. Weiss, B. G. Redman, J. G. Jakowatz, et al. Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group J. Clin. Oncol., April 15, 2002; 20(8): 2058 - 2066. [Abstract] [Full Text] [PDF]